FDA Brief

Warning letters Food

FDA warning letter to

Lone Star Botanicals Inc.

High riskIssued Nov 6, 2023Posted Jan 2, 2024Division of Human and Animal Food Operations East III

FDA cited Lone Star Botanicals for unsanitary ready-to-eat seasonings and unapproved drug claims for Dr. Botanical Health products.

What happened

FDA inspected the Tyler, TX food manufacturing facility April 17-21, 2023 and issued a Form FDA 483 listing deviations. FDA found serious CGMP (current good manufacturing practice) and preventive-control violations for ready-to-eat seasoning blends, including a missing food safety plan, allergen, pathogen, and supply-chain controls, and an allergen label error. FDA also reviewed the company website in July and October 2023 and product labels/brochure; it found disease-treatment claims that make Dr. Botanical Health products unapproved new drugs.

What FDA found

  1. The company did not have a required written food safety plan, hazard analysis, or implemented preventive controls.

    21 CFR 117.126(a)(1), 117.130(a), 117.135(a)(1)
  2. The company did not identify or control allergens, and a Steak Beast Unleashed All Purpose Rub ingredient list omitted butter powder, which contains milk.

    section 403(w) of the Act [21 U.S.C. § 343(w)]; 21 CFR 117.135(c)(2)
  3. The company did not identify or control Salmonella as an environmental pathogen and used a household cleaner on food-contact surfaces without sanitizer or environmental monitoring.

    21 CFR 117.130(c)(1)(ii), 117.135(c)(3), 117.165(a)(3)
  4. The company lacked a supply-chain program for bacterial pathogens in spices, including approved suppliers and supplier verification activities.

    21 CFR 117.405(a)(1), 117.410, 117.430(b)
  5. The company did not identify or control mycotoxins in white pepper, cayenne pepper, and paprika and lacked a supply-chain program for them.

    21 CFR 117.405(a)(1), 117.410
  6. The company marketed Dr. Botanical Health products with claims to treat or prevent diseases, making them unapproved new drugs and misbranded because they lack adequate directions for use.

    section 201(g)(1)(B) [21 U.S.C. 321(g)(1)(B)], 201(p) [21 U.S.C. 321(p)], 505(a) [21 U.S.C. 355(a)], 502(f)(1) [21 U.S.C. 352(f)(1)]

What FDA wants

FDA asks the company to correct the violations and respond in writing; the provided letter text does not state a response deadline.

Who should pay attention

  • food brands and co-packers using dry spice or seasoning suppliers
  • retailers and online sellers of Dr. Botanical Health supplement powders
  • consumers with milk allergies or who rely on disease-treatment claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. ABC Food Corp

    ABC Food Corp's ready-to-eat rice noodles and tofu were made without required hazard analysis and preventive controls.

    High risk
  2. IF Co-Pack, LLC dba Initiative Foods

    FDA warns Initiative Foods, a Sanger, California baby food maker, that it failed to control patulin, a mold toxin, in fruit pouches.

    High risk
  3. Rama Food Manufacture Corp.

    FDA warns Rama Food Manufacture after inspections found insanitary conditions and preventive-control failures at its California ready-to-eat rice noodle plants.

    High risk
  4. Lewis Sausage Company Inc.

    FDA found Salmonella and Listeria in contract-made pet food from Lewis Sausage and says its pathogen controls are inadequate.

    High risk